Leukotrienes (i.e., products of the
5-lipoxygenase pathway) are thought to be contributors to lung pathologies. Moreover, eosinophils have been linked with pulmonary
leukotriene activities both as potential sources of these mediators and as responding effector cells. The objective of the present study was to define the role(s) of
leukotrienes in the lung pathologies accompanying eosinophil-associated chronic respiratory
inflammation. A transgenic mouse model of chronic T helper (Th) 2-driven
inflammation expressing
IL-5 from T cells and human
eotaxin-2 locally in the lung (I5/hE2) was used to define potential in vivo relationships among eosinophils,
leukotrienes, and chronic Th2-polarized
pulmonary inflammation. Airway levels of cys-
leukotrienes and
leukotriene B4 (
LTB4) are both significantly elevated in I5/hE2 mice. The eosinophil-mediated
airway hyperresponsiveness (AHR) characteristic of these mice was abolished in the absence of
leukotrienes (i.e.,
5-lipoxygenase-deficient I5/hE2). More importantly, the loss of
leukotrienes led to an unexpectedly significant decrease in
collagen deposition (i.e.,
pulmonary fibrosis) that accompanied elevated levels of IL-4/-13 and TGF-β in the lungs of I5/hE2 mice. Further studies using mice deficient for the
LTB4 receptor (BLT-1(-/-)/I5/hE2) and I5/hE2 animals administered a cys-
leukotriene receptor antagonist (
montelukast) demonstrated that the AHR and the enhanced
pulmonary fibrosis characteristic of the I5/hE2 model were uniquely cys-
leukotriene-mediated events. These data demonstrate that, similar to
allergen challenge models of wild-type mice, cys-
leukotrienes underlie AHR in this transgenic model of severe pulmonary Th2
inflammation. These data also suggest that an underappreciated link exists among eosinophils, cys-
leukotriene-mediated events, and fibrotic remodeling associated with elevated levels of IL-4/-13 and TGF-β.